DS
MYGN icon

David Shaw’s Myriad Genetics MYGN Stock Holding History

David Shaw’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-19,600
Closed -$506K – 3549
2017
Q2 		$506K Sell
19,600
-800
-4% -$17K ﹤0.01% 2808
2017
Q1 		$392K Buy
+20,400
New +$361K ﹤0.01% 2849

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's MYGN Position: Q2 2026 in Review

David Shaw increased its Myriad Genetics (MYGN) stake by 1.8% in Q2 2026, buying an estimated $374K and bringing the position to 4,582,083 shares worth $26.2M. The position accounts for 0.01% of the portfolio, ranked #1119.

David Shaw first reported a position in MYGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $179M in Q3 2018. 195 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • David Shaw held 4,582,083 shares of Myriad Genetics worth $26.2M as of Q2 2026.
  • David Shaw bought 82,359 Myriad Genetics shares in Q2 2026, an estimated $374K.
  • Myriad Genetics made up 0.01% of David Shaw's portfolio in Q2 2026, its #1119 holding.
  • David Shaw first reported a position in Myriad Genetics in Q2 2013 and has held it in 53 quarters since.
  • David Shaw's Myriad Genetics position peaked at $179M in Q3 2018.
  • 195 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.